L01XX46 • olaparib • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Olaparib is a medication used for the treatment of certain types of cancer, such as ovarian, breast, or prostate cancer, associated with BRCA gene mutations. It is a poly(ADP-ribose) polymerase (PARP) inhibitor that interferes with DNA repair in cancer cells, leading to their death.
The medication is taken orally, usually twice daily, as directed by your doctor. It is important to follow the treatment regimen and undergo regular check-ups to monitor effectiveness and potential side effects.
Side effects may include nausea, fatigue, anemia, diarrhea, or, in rare cases, myelodysplastic syndrome.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of olaparib.
Substance: olaparib
Date of last drug list: 10-04-2026
Commercial code: W64661001
Concentration: 150mg
Pharmaceutical form: film-coated tablets
Quantity: 56
Product type: original
Price: 10886.28 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ASTRAZENECA UK LIMITED - MAREA BRITANIE
Holder: ASTRAZENECA AB - SUEDIA
Number: 959/2014/04
Shelf life: 3 years
